Autonomix Medical Secures Major Patent for Catheter Technology
Autonomix Medical Secures Major Patent for Catheter Technology
Patent strengthens Autonomix’s intellectual property position in nerve mapping, supporting a mission to advance minimally invasive therapies.
The company expands its patent portfolio, now boasting over 80 issued patents and 40 pending applications.
The Woodlands, TX – In a significant move for the medical device industry, Autonomix Medical, Inc. (NASDAQ: AMIX), focused on precision nerve-targeted treatments, recently received an important patent from the United States Patent and Trademark Office (USPTO). This patent, designated as U.S. Patent No. 12,257,071, is centered on innovative catheter-based systems designed to integrate nerve mapping with advanced radiofrequency (RF) ablation technology. This cutting-edge solution aims to improve patient outcomes through highly targeted, minimally invasive techniques for treating various nerve-related conditions.
Brad Hauser, CEO of Autonomix, expressed enthusiasm about the patent's issuance, calling it a pivotal milestone for the company. He stated, "This innovative technology enhances our intellectual property position in the nerve-focused therapeutics arena, providing us the necessary tools to protect our solutions while enhancing care for healthcare providers and their patients. We believe this patent plays a crucial role in our portfolio, aligning with our mission to transform the treatment landscape of nerve-related disorders."
The newly granted patent encompasses a range of groundbreaking features intended to equip healthcare professionals with advanced tools for patient care. Key attributes of the technology include deployable microfingers embedded with sensors that facilitate real-time physiological monitoring. This integrated system allows for simultaneous mapping, stimulating, ablating, and assessing nerve activity, providing comprehensive support for medical procedures. Additionally, it comprises feedback-driven control for various treatment applications, such as RF ablation and ultrasound, and is designed to adapt its therapeutic output based on real-time data from multiple inputs like electromyography (EMG) and bioimpedance.
Autonomix's distinct technology platform utilizes a catheter-based microchip sensing array antenna capable of enhancing sensitivity in detecting neural signals. This capability is poised to revolutionize how nervous system diseases are diagnosed and treated, particularly for conditions like chronic pain and hypertension. By pinpointing overactive nerves, Autonomix can apply its proprietary RF ablation technology to target those nerves, pushing forward the field of precision medicine.
The company has ambitious plans on the horizon, with intentions to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials within the next year. These trials will be pivotal in commercializing the Autonomix Sensing and RF Ablation System as a legitimate treatment option for pain caused by pancreatic cancer, showcasing the company’s commitment to innovation in nerve-targeted treatments.
For individuals eager to learn more about the technology that Autonomix Medical is developing, further information can be found on their official website.
About Autonomix Medical, Inc.
Autonomix is dedicated to advancing innovative technologies that transform the diagnosis and treatment of diseases linked to the nervous system. With a technology platform that includes a catheter-based microchip sensing array, the company aims to enhance the detection and differentiation of neural signals, facilitating new methods of treatment previously thought unattainable. Initially focused on pain management, with a strong emphasis on pancreatic cancer pain, Autonomix is also developing its technology for applications across cardiology, hypertension, and more.
Investor and media inquiries can be directed to JTC Team, LLC, with Jenene Thomas available for contact at 908-824-0775 or through the official email.
Frequently Asked Questions
What is the significance of the new patent issued to Autonomix Medical?
The patent strengthens Autonomix's IP position and enhances their innovative catheter-based technology aimed at treating nerve-related disorders.
How does the Autonomix technology benefit treating chronic pain?
The technology allows for precision-guided treatment by targeting overactive nerves, providing a less invasive alternative to current pain management strategies.
What features does the new catheter-based technology include?
The technology includes real-time physiological monitoring, integrated mapping, stimulation, ablation, and feedback control for varied treatment procedures.
What are Autonomix's primary future plans following this patent?
They plan to submit an Investigational Device Exemption and start clinical trials to commercialize their system for treating pancreatic cancer pain.
What does Autonomix Medical focus on overall?
Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, particularly through minimally invasive methods.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
